CRON · Cronos Group Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.21M | - | $36.34M | $33.45M | $32.26M | - | $34.26M | $27.76M | $25.29M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | $19.15M | - | $18.33M | $14.50M | $13.73M | - | $3.61M | $6.30M | $4.48M | - |
| R&D | $1.41M | - | $1.34M | $929.0K | $793.0K | - | $1.24M | $962.0K | $997.0K | - |
| SG&A | $11.74M | - | $9.25M | $10.54M | $9.31M | - | $12.76M | $12.77M | $8.91M | - |
| Total Operating Expenses | $20.99M | - | $18.84M | $19.83M | $17.81M | - | $37.27M | $21.86M | $20.43M | - |
| D&A | $3.73M | - | $354.0K | $867.0K | $2.84M | - | $1.10M | $1.02M | $1.73M | - |
| Operating Income | ($1.83M) | - | ($503.0K) | ($5.32M) | ($4.07M) | - | ($33.66M) | ($15.56M) | ($15.95M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $2.43M | - | ($1.32M) | ($525.0K) | ($455.0K) | - | ($2.71M) | ($2.17M) | ($558.0K) | - |
| Net Income | $13.75M | - | $25.96M | ($39.71M) | $6.12M | - | $8.35M | ($8.76M) | ($2.24M) | - |
| EPS - Basic | $0.04 | - | $0.07 | ($0.10) | $0.02 | - | $0.02 | ($0.02) | ($0.01) | - |
| EPS - Diluted | $0.04 | - | $0.07 | ($0.10) | $0.02 | - | $0.02 | ($0.02) | ($0.01) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $821.86M | $791.79M | $784.17M | $794.42M | $797.82M | $858.80M | $862.03M | $848.19M | $855.11M | $669.29M |
| Accounts Receivable | $32.96M | $34.10M | $27.09M | $26.62M | $18.71M | $15.46M | $20.48M | $16.18M | $15.34M | $13.98M |
| Inventory | $48.68M | $46.75M | $48.17M | $42.14M | $34.60M | $33.15M | $47.25M | $29.18M | $30.64M | $30.50M |
| Accounts Payable | $10.28M | $11.64M | $10.87M | $12.14M | $9.50M | $16.97M | $6.53M | $7.84M | $9.40M | $12.13M |
| Current Assets | $927.88M | $944.09M | $922.15M | $927.15M | $918.58M | $936.11M | $959.17M | $935.28M | $942.22M | $933.31M |
| Total Assets | $1.17B | $1.20B | $1.18B | $1.18B | $1.15B | $1.17B | $1.18B | $1.09B | $1.11B | $1.14B |
| Current Liabilities | $42.42M | $48.19M | $41.07M | $37.61M | $33.05M | $49.70M | $39.56M | $33.06M | $33.42M | $41.40M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $48.30M | $54.18M | $46.36M | $45.02M | $39.06M | $55.33M | $52.82M | $35.26M | $35.76M | $43.96M |
| Stockholders' Equity | $1.07B | $1.09B | $1.08B | $1.08B | $1.07B | $1.06B | $1.08B | $1.06B | $1.08B | $1.10B |
| Retained Earnings | $460.54M | $447.76M | $450.03M | $424.08M | $463.82M | $457.71M | $414.00M | $405.65M | $414.48M | $416.72M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.90M | - | - | - | ($2.10M) | - | - | - | ($2.20M) | - |
| Investing Cash Flow | $38.03M | - | - | - | ($55.36M) | - | - | - | $189.56M | - |
| Financing Cash Flow | ($18.27M) | - | - | - | ($2.93M) | - | - | - | ($645.0K) | - |
| CapEx | $1.88M | - | - | - | $15.26M | - | - | - | $1.72M | - |
| Free Cash Flow | $9.02M | - | - | - | ($17.35M) | - | - | - | ($3.93M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 42.4% | - | 50.4% | 43.4% | 42.6% | - | 10.5% | 22.7% | 17.7% | - |
| Operating margin | -4.1% | - | -1.4% | -15.9% | -12.6% | - | -98.2% | -56.1% | -63.1% | - |
| EBITDA margin | 4.2% | - | -0.4% | -13.3% | -3.8% | - | -95.0% | -52.4% | -56.2% | - |
| Net margin | 30.4% | - | 71.4% | -118.7% | 19.0% | - | 24.4% | -31.5% | -8.9% | - |
| Free cash flow margin | 20.0% | - | - | - | -53.8% | - | - | - | -15.5% | - |
| FCF / Net income | 0.66 | - | - | - | -2.83 | - | - | - | 1.75 | - |
| R&D / Revenue | 3.1% | - | 3.7% | 2.8% | 2.5% | - | 3.6% | 3.5% | 3.9% | - |
| SG&A / Revenue | 26.0% | - | 25.5% | 31.5% | 28.9% | - | 37.2% | 46.0% | 35.2% | - |
| Effective tax rate | 15.0% | - | -5.3% | - | -8.0% | - | -48.0% | - | - | - |
| Return on assets | 1.2% | - | 2.2% | -3.4% | 0.5% | - | 0.7% | -0.8% | -0.2% | - |
| Return on equity | 1.3% | - | 2.4% | -3.7% | 0.6% | - | 0.8% | -0.8% | -0.2% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 21.87 | 19.59 | 22.45 | 24.65 | 27.80 | 18.84 | 24.24 | 28.29 | 28.19 | 22.54 |
| Quick ratio | 20.73 | 18.62 | 21.28 | 23.53 | 26.75 | 18.17 | 23.05 | 27.41 | 27.28 | 21.81 |
| Cash ratio | 19.37 | 16.43 | 19.09 | 21.12 | 24.14 | 17.28 | 21.79 | 25.66 | 25.59 | 16.17 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.09 | 1.09 | 1.09 | 1.08 | 1.10 | 1.09 | 1.03 | 1.03 | 1.04 |
| Liabilities / Assets | 0.04 | 0.05 | 0.04 | 0.04 | 0.03 | 0.05 | 0.04 | 0.03 | 0.03 | 0.04 |
| Efficiency | ||||||||||
| Asset turnover | 0.04 | - | 0.03 | 0.03 | 0.03 | - | 0.03 | 0.03 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 266d | - | 272d | 290d | 212d | - | 218d | 213d | 221d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 62.7x | - | 39.7x | - | 90.5x | - | 109.5x | - | - | - |
| P / B | 0.9x | - | 1.0x | 0.7x | 0.7x | - | 0.8x | 0.8x | 0.9x | - |
| P / S | 21.2x | - | 29.5x | 22.0x | 21.7x | - | 24.7x | 32.1x | 39.4x | - |
| EV / EBITDA | 72.0x | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 40.1% | - | 6.1% | 20.5% | 27.6% | - | 38.1% | 46.0% | 25.5% | - |
| Revenue CAGR (3y) | 30.9% | - | 20.2% | 13.2% | 8.8% | - | 18.9% | 21.1% | 26.1% | - |
| Revenue CAGR (5y) | 29.1% | - | 26.2% | 27.6% | 30.8% | - | - | - | - | - |
| Gross profit growth (YoY) | 39.5% | - | 407.7% | 130.3% | 206.4% | - | -9.0% | 103.2% | 88.4% | - |
| Operating income growth (YoY) | 55.0% | - | 98.5% | 65.8% | 74.5% | - | -54.6% | 24.5% | 27.5% | - |
| Net income growth (YoY) | 124.6% | - | 210.9% | -353.5% | - | - | - | -4.7% | 88.3% | - |
| EPS growth (YoY) | 100.0% | - | 250.0% | -400.0% | - | - | - | 60.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | -18.1% | - | -36.9% | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -341.8% | - | - | - | 91.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 0.7% | 2.8% | 0.1% | 2.2% | -0.9% | -3.2% | -3.4% | -7.1% | -4.7% | -3.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$146.59M totalCannabis Flower$108.48M · 74.0%
Cannabis Extracts$37.70M · 25.7%
Product And Service Other$411.0K · 0.3%
Geographic
$146.59M totalCA$90.33M · 61.6%
IL$41.80M · 28.5%
Other Countries$14.46M · 9.9%
Peer comparison
Same SIC group: Medicinal Chemicals & Botanical Products
Comparing Cronos Group Inc. against the 5 most active filers in the same SIC group.